Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. - Wikidata - awgldk - TriplyDB

Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection.

Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection.

http://www.wikidata.org/entity/Q33683302

about

Hemostatic disorders of the menopausal period: the role of microRNA Serum uric acid concentration is associated with hypertensive retinopathy in hypertensive chinese adults.Hormone replacement therapy in women with a history of breast cancer.Hyperhomocysteinaemia and cardiovascular risk in female ovariectomized rats: role of folic acid and hormone replacement therapy.Apolipoprotein e4 allele and endothelium-dependent arterial dilation in Type 2 diabetes mellitus without angiopathy.Serum lipids and apolipoproteins in Greek postmenopausal women: association with estrogen, estrogen-progestin, tibolone and raloxifene therapy.Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.

P2860

Q26795566-238E8EEB-1DF5-4528-B37D-F23E00C4E6AF Q33759523-807C4D43-B853-442D-B56A-D5E009408FEF Q35081294-1E30D821-839E-4962-ACB5-13DD94F9E120 Q43922701-2BB76BCC-DB7F-4947-BF59-05BF072C17E9 Q44435400-35A3EE4B-3E0A-46B5-A951-54F3EC113A9B Q44571336-25C8F6C4-61E3-4501-9EA9-15BC6785D63D Q45043374-A961BD95-2BF2-4638-8C65-57A9D03EE7BA

P2860

Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection.

http://www.wikidata.org/entity/Q33683302

description

1999 nî lūn-bûn

@nan

1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Postmenopausal hormone replace ...... and cardiovascular protection.

@ast

Postmenopausal hormone replace ...... and cardiovascular protection.

@en

type

label

Postmenopausal hormone replace ...... and cardiovascular protection.

@ast

Postmenopausal hormone replace ...... and cardiovascular protection.

@en

prefLabel

Postmenopausal hormone replace ...... and cardiovascular protection.

@ast

Postmenopausal hormone replace ...... and cardiovascular protection.

@en

P1433

Q33683302-4602E01D-51D1-41F1-8947-8D8241F90DF3

P1476

Q33683302-090876D4-667B-4A48-B7D4-9B3BD3C1D77F

P2093

Q33683302-27CFE2DD-6250-4010-BB1D-2B6A7087D3A4

Q33683302-387A629E-689B-4DFF-A550-BAEA7795C8F8

Q33683302-824BB6C2-AB6B-41C3-95A6-58D430FDDC20

Q33683302-CC213FA0-15EA-4D6E-A329-7B485ED1953A

Q33683302-EB46D4B9-AC83-41DB-9DE6-796A7DCBEBDF

P2860

Q33683302-0398D708-8668-4DE9-B2E0-E59AA8EE387A

Q33683302-09641724-1F76-47B2-A888-DA55BED846B5

Q33683302-0BE1EA3A-5A04-4610-AD0B-CAF23054DC06

Q33683302-17DACB90-A4EB-46A6-BDDB-4383102E8A62

Q33683302-18C59196-557F-495A-8F91-41CC3B4EBEE3

Q33683302-1DCC5614-9101-425C-92DA-4E5EF3DDD298

Q33683302-1DEBA6AA-C0D8-42DB-86AE-5D1F1E68671D

Q33683302-207A6405-DE09-4D7F-BC96-2C5DFB9929DB

Q33683302-21CC41CD-02B7-4EF5-853F-3A9709C2C1A5

Q33683302-2BB4E428-AB99-4402-A0FA-7E48053800EA

P304

Q33683302-D3B6CE93-7C05-4CCE-A47D-EA6F6ADBC4B3

P31

Q33683302-6DD7A8BC-41C0-4637-96E3-441A57C0D15B

P356

Q33683302-73DB0E53-F873-40B6-BA3B-9A8EB78177B4

P433

Q33683302-4015E585-DEEB-41F5-9AC8-FA98CEAF1F03

P478

Q33683302-B004C9D6-BA72-4CB1-AECA-B57B4A7803E0

P577

Q33683302-13EF35EB-3804-4F1F-959A-0E211D8380E5

P698

Q33683302-E3F3AA16-B995-425E-8E7A-EE6C822E7EA4

P356

09513599909167545

P1433

Gynecological Endocrinology

P1476

Postmenopausal hormone replace ...... and cardiovascular protection.

@en

P2093

Kenemans P

http://www.w3.org/2001/XMLSchema#string

Mijatovic V

http://www.w3.org/2001/XMLSchema#string

Netelenbos JC

http://www.w3.org/2001/XMLSchema#string

Stehouwer CD

http://www.w3.org/2001/XMLSchema#string

van der Mooren MJ

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study.

Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery.

17 beta-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease.

Postmenopausal hormone therapy and mortality.

Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.

Lipoprotein (a) concentrations in postmenopausal women taking norethisterone

L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.

Endothelium-independent relaxation of rabbit coronary artery by 17 beta-oestradiol in vitro

P304

130-144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/09513599909167545

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

1999-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10399059

http://www.w3.org/2001/XMLSchema#string